Company Encyclopedia
View More
name
Abcellera Biologics
ABCL.US
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.
746.92 B
ABCL.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking46/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-16.81%E
    • Profit Margin-485.99%E
    • Gross Margin-514.49%E
  • Growth ScoreC
    • Revenue YoY7.17%C
    • Net Profit YoY2.34%C
    • Total Assets YoY-2.64%D
    • Net Assets YoY-10.58%D
  • Cash ScoreC
    • Cash Flow Margin-20.58%D
    • OCF YoY7.17%C
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio28.91%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?

    AbCellera Biologics Inc. (NASDAQ:ABCL) is transitioning from a partnership model to developing its own clinical assets. This strategic shift was reaffirmed at the Stifel 2025 Healthcare Conference on November 13. Wall Street maintains a buy stance on the stock amid this business model evolution.

    MSN·
    US
    ABCL
    -1.37%
    MSN·
    US
    ABCL
    -1.37%

    Can Dr. Quake’s Arrival Offset AbCellera Biologics (ABCL) Board Changes and Widening Losses?

    AbCellera Biologics appointed Dr. Stephen Quake as an independent director amidst board changes and widening losses. The company reported Q3 2025 revenue growth to $8.96 million but net losses increased to $57.12 million. Dr. Quake's appointment is seen as a leadership boost, yet does not alter short-term clinical trial catalysts or mitigate high R&D spending risks. The company forecasts $123.3 million revenue and $17.5 million earnings by 2028, with a fair value estimate of $10.20, offering a 176% upside. Opinions on fair value vary widely, reflecting differing views on pipeline progress and financial improvement.

    Simplywall·
    US
    ABCL
    -1.37%
    Simplywall·
    US
    ABCL
    -1.37%

    AbCellera Appoints Dr. Stephen Quake to Board

    AbCellera Biologics announced the appointment of Dr. Stephen Quake to its Board of Directors on November 10, 2025, enhancing its commitment to scientific excellence. Dr. Quake's expertise in genomics aligns with the company's goals. Andrew Lo resigned from the board after significant contributions since 2021. The current analyst rating for ABCL stock is a Hold with a $4.00 price target, while Spark's AI Analyst rates it as Neutral, citing financial challenges and bearish momentum. AbCellera focuses on developing antibody-based medicines in various fields, with a market cap of $1.21B.

    Tip Ranks·
    US
    ABCL
    -1.37%
    Tip Ranks·
    US
    ABCL
    -1.37%

    AbCellera Biologics’ Earnings Call: Key Insights

    AbCellera Biologics held its Q3 earnings call, highlighting its transition to a clinical-stage biotech with ongoing Phase I trials for ABCL635 and ABCL575. The company reported a strong liquidity position of $680 million but faced challenges with a net loss of $57 million and rising R&D expenses of $55 million. Revenue increased to $9 million, driven by research fees. Stagnation in partner-initiated programs remains a concern. Looking ahead, AbCellera aims to advance more candidates into IND-enabling studies, with new Chief Medical Officer Dr. Sarah Noonberg expected to enhance clinical efforts.

    Tip Ranks·
    US
    ABCL
    -1.37%
    Tip Ranks·
    US
    ABCL
    -1.37%

    AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns

    AbCellera Biologics Inc. has appointed Dr. Stephen Quake as an independent director to its Board of Directors, known for his expertise in biophysics, microfluidics, and genomics. This appointment follows the resignation of Andrew W. Lo, Ph.D., from his position as an independent director.

    Reuters·
    US
    ABCL
    -1.37%
    Reuters·
    US
    ABCL
    -1.37%